Background. Cardiovascular disease (CVD) remains a significant problem in Chronic Kidney Disease (CKD). Subclinical atherosclerosis identified by noninvasive methods could improve CVD risk prediction in CKD but these methods are often unavailable. We therefore systematically reviewed whether circulating levels of Matrix Metalloproteinases (MMPs) and tissue inhibitors (TIMPs) are associated with subclinical atherosclerosis in CKD, as this would support their use as biomarkers or pharmacologic targets. Methods. All major electronic databases were systematically searched from inception until May 2015 using appropriate terms. Studies involving CKD patients with data on circulating MMPs levels and atherosclerosis were considered and subjected to...
Background: Chronic kidney disease (CKD) predisposes to accelerated atherosclerosis that is measured...
Aim We aimed to investigate the factors affecting the development of atherosclerosis and the role of...
Background/Aims: The incidence of cardiovascular disease in patients with chronic kidney disease (CK...
Background. Cardiovascular disease (CVD) remains a significant problem in Chronic Kidney Disease (CK...
Background. Cardiovascular disease (CVD) remains a significant problem in Chronic Kidney Disease (CK...
Cardiovascular disease is the leading cause of mortality in chronic kidney disease (CKD). As matrix ...
Cardiovascular disease is the leading cause of mortality in chronic kidney disease (CKD). As matrix ...
Circulating matrix metalloproteinase (MMP)-2, -3 and -9 are well recognized in predicting cardiovasc...
BACKGROUND: Circulating matrix metalloproteinase (MMP)-2, -3 and -9 are well recognized in predictin...
: Chronic Kidney Disease (CKD) represents a risk factor for fatal and nonfatal cardiovascular (CV) e...
End-stage kidney disease (ESKD) is a major health problem associated with very high morbidity and mo...
Background and aims: Previous proteomics efforts in patients with chronic kidney disease (CKD) have ...
End-stage kidney disease (ESKD) is a major health problem associated with very high morbidity and mo...
Coll et al. show that across the spectrum of chronic kidney disease (CKD), atherosclerosis severity ...
Objective was to assess whether the concentration of malondialdehyde (MDA) as a marker of lipid pero...
Background: Chronic kidney disease (CKD) predisposes to accelerated atherosclerosis that is measured...
Aim We aimed to investigate the factors affecting the development of atherosclerosis and the role of...
Background/Aims: The incidence of cardiovascular disease in patients with chronic kidney disease (CK...
Background. Cardiovascular disease (CVD) remains a significant problem in Chronic Kidney Disease (CK...
Background. Cardiovascular disease (CVD) remains a significant problem in Chronic Kidney Disease (CK...
Cardiovascular disease is the leading cause of mortality in chronic kidney disease (CKD). As matrix ...
Cardiovascular disease is the leading cause of mortality in chronic kidney disease (CKD). As matrix ...
Circulating matrix metalloproteinase (MMP)-2, -3 and -9 are well recognized in predicting cardiovasc...
BACKGROUND: Circulating matrix metalloproteinase (MMP)-2, -3 and -9 are well recognized in predictin...
: Chronic Kidney Disease (CKD) represents a risk factor for fatal and nonfatal cardiovascular (CV) e...
End-stage kidney disease (ESKD) is a major health problem associated with very high morbidity and mo...
Background and aims: Previous proteomics efforts in patients with chronic kidney disease (CKD) have ...
End-stage kidney disease (ESKD) is a major health problem associated with very high morbidity and mo...
Coll et al. show that across the spectrum of chronic kidney disease (CKD), atherosclerosis severity ...
Objective was to assess whether the concentration of malondialdehyde (MDA) as a marker of lipid pero...
Background: Chronic kidney disease (CKD) predisposes to accelerated atherosclerosis that is measured...
Aim We aimed to investigate the factors affecting the development of atherosclerosis and the role of...
Background/Aims: The incidence of cardiovascular disease in patients with chronic kidney disease (CK...